Search

Your search keyword '"Abiko, A."' showing total 8,716 results

Search Constraints

Start Over You searched for: Author "Abiko, A." Remove constraint Author: "Abiko, A."
8,716 results on '"Abiko, A."'

Search Results

157. Supplementary Figure legend from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma

158. Supplementary Table 3 from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma

159. Supplementary Table 7 from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma

160. Supplementary Table 8 from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma

161. Supplementary Table 6 from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma

162. Data from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma

163. Supplementary Figure 2 from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma

164. Supplementary Table 9 from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma

165. Supplementary Table 4 from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma

166. Supplementary Table 5 from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma

167. Supplementary Table 1 from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma

168. Supplementary Figure 1 from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma

169. Supplementary Table 2 from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma

182. Serum lactate dehydrogenase is a possible predictor of platinum resistance in ovarian cancer

183. Mapping quantitative trait loci for water uptake of rice under aerobic conditions

184. UGT1A1 polymorphism has a prognostic effect in patients with stage IB or II uterine cervical cancer and one or no metastatic pelvic nodes receiving irinotecan chemotherapy: a retrospective study

185. A high-resolution description of β1-adrenergic receptor functional dynamics and allosteric coupling from backbone NMR

186. Pericardial tamponade during pembrolizumab treatment in a patient with advanced lung adenocarcinoma: A case report and review of the literature

187. Hemobilia-a rare complication after laparoscopic cholecystectomy

188. Flexible Resource Block Allocation to Multiple Slices for Radio Access Network Slicing Using Deep Reinforcement Learning

189. Highly conserved binding region of ACE2 as a receptor for SARS-CoV-2 between humans and mammals

190. Proteomic and microbiota analyses of the oral cavity during psychological stress.

191. Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B.

192. Drought Analysis Using Standardized Evapotranspiration and Aridity Index at Bilate Watershed: Sub-Basins of Ethiopian Rift Valley

200. Sustentabilidade urbana: dimensões conceituais e instrumentos legais de implementação

Catalog

Books, media, physical & digital resources